| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 22.087 | 44.090 | 0 | 17.259 | 8.152 | - | - |
| Total Income - EUR | - | - | - | 22.442 | 45.229 | 3.365 | 19.437 | 8.225 | - | - |
| Total Expenses - EUR | - | - | - | 12.612 | 51.391 | 19.350 | 17.438 | 18.162 | - | - |
| Gross Profit/Loss - EUR | - | - | - | 9.830 | -6.161 | -15.984 | 1.999 | -9.937 | - | - |
| Net Profit/Loss - EUR | - | - | - | 9.609 | -6.602 | -15.984 | 1.826 | -10.018 | - | - |
| Employees | - | - | - | 1 | 1 | 1 | 1 | 1 | - | - |
Check the financial reports for the company - Tinca Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - |
| Current Assets | - | - | - | 19.272 | 20.863 | 4.139 | 6.203 | 2.010 | - | - |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - |
| Receivables | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - |
| Cash | - | - | - | 19.272 | 20.863 | 4.139 | 6.203 | 2.010 | - | - |
| Shareholders Funds | - | - | - | 2.404 | -4.245 | -20.149 | -17.875 | -27.949 | - | - |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | - | - |
| Debts | - | - | - | 16.867 | 25.107 | 24.288 | 24.078 | 29.958 | - | - |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Tinca Pharma S.r.l.